RE: R N S Operational Update on Paraytec21 Jul 2022 08:33
The last paragraph in todays RNS states
Trevor Brown, CEO of Braveheart, commented: "The significant investment of scientific, technological and financial resources in the CX300 program over the past two years has been against a continuously changing COVID-19 background, but we are satisfied that we have adapted continuously to remain relevant. We believe our COVID-19 test, once verified by the initial clinical study, will be amongst the most effective and most advanced in development. We will therefore explore how Paraytec can offer it as a commercially available public testing service as an alternative to monetizing it via the outright sale of the technology as previously envisaged."
I fully support this change in direction rather than selling the technology licence and all IP to a company for a large fast buck we can have a very large constant revenue stream from testing. This can then possibly provide a regular dividend and provide finance to develop wider services and investment in other companies in the future !
The Future is Bright ! The Future is Braveheart !
StarKnight